July 22nd, 2019 – JANESVILLE, WI – SHINE Medical Technologies LLC today announced that the company has filed an application with the U.S. Nuclear Regulatory Commission to produce medical isotopes, including molybdenum-99 (Mo-99), iodine-131 and xenon-133, at its production facility in Janesville, WI. SHINE broke ground on the facility in May of this year.
SHINE’s facility will be the first of its kind in the world, utilizing the company’s patented technology to produce Mo-99 and other isotopes used in more than 40 million medical imaging procedures every year.
“Completing our NRC operating license application signals the transition of our efforts to establish a secure global supply of medical isotopes from the design and engineering phase to the construction and delivery phase,” said Greg Piefer, founder and CEO of SHINE. “This required an extraordinary effort by our world-class team, including more than 150,000 person-hours of work. Time and time again, they have stepped up and delivered high-quality products, demonstrating SHINE’s commitment to supplying lifesaving medical tracers and therapeutics to an underserved and growing global market.”
There are only four major facilities in the world that produce one of the most important isotopes, Mo-99, despite its widespread use in heart stress tests, cancer staging and other medical applications. Chronic global shortages of Mo-99 routinely and significantly affect the diagnosis and treatment of patients around the world.
“SHINE’s fusion-fission technology enables us to produce Mo-99 more safely, cleanly and efficiently than conventional reactor-based technologies,” Piefer said. “The completion of this milestone should signal to the market that SHINE is on track to help end isotope shortages once the Janesville production facility, capable of producing more than one-third of global demand for Mo-99, is online.”
“The best way to secure the future is to create it and the submission of our NRC application is the latest example of SHINE creating an exciting, productive future,” said Jim Costedio, SHINE’s vice president of regulatory affairs and quality. “SHINE’s application represents years of tireless work by a team that included not just our regulatory and engineering groups, but outstanding people from across the company. We look forward to working with the NRC staff during the review of our application.”